Journal
TETRAHEDRON
Volume 76, Issue 2, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.tet.2019.130819
Keywords
Duchenne muscular dystrophy; Utrophin modulator; Phosphinate; Enantioselective synthesis; Preclinical candidate
Categories
Funding
- Summit Therapeutics plc
- Medical Research Council [1501AV003/CA2]
- Duchenne UK
- MRC [MR/N010698/1] Funding Source: UKRI
Ask authors/readers for more resources
Following on from ezutromid, the first-in-class benzoxazole utrophin modulator that progressed to Phase 2 clinical trials for the treatment of Duchenne muscular dystrophy, a new chemotype was designed to optimise its physicochemical and ADME profile. Herein we report the synthesis of SMT022357, a second generation utrophin modulator preclinical candidate, and an asymmetric synthesis of its constituent enantiomers. The pharmacological properties of both enantiomers were evaluated in vitro and in vivo. No significant difference in the activity or efficacy was observed between the two enantiomers; activity was found to be comparable to the racemic mixture. (C) 2019 The Authors. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available